4.1 Article

Transition of average drug-to-antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography-tandem mass spectrometry

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer

Bob T. Li et al.

Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Medicine, General & Internal

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

J. Cortes et al.

Summary: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, trastuzumab deruxtecan was associated with a lower risk of disease progression or death compared to trastuzumab emtansine. However, treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi et al.

Summary: Trastuzumab deruxtecan demonstrated significantly longer progression-free and overall survival compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Pharmacology & Pharmacy

Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan

Ophelia Yin et al.

Summary: Trastuzumab deruxtecan (T-DXd) has been approved for HER2-positive metastatic breast cancer and gastric cancer, with the 5.4 mg/kg every-3-weeks dosage justified based on exposure-efficacy analysis. Intact T-DXd area under the concentration-time curve was significantly associated with objective response rate, while no significant exposure-response relationships were observed for duration of response or progression-free survival. Higher exposure to T-DXd or released drug was correlated with increased adverse events, suggesting a dose-response relationship with higher ORR and toxicity at 6.4 mg/kg compared to 5.4 mg/kg.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kohei Shitara et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Biochemical Research Methods

Quantitative bioanalysis of antibody-conjugated payload in monkey plasma using a hybrid immuno-capture LC-MS/MS approach: Assay development, validation, and a case study

Ang Liu et al.

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2015)